As of 2024-12-13, the Fair Value of Innate Pharma SA (IPH.PA) is -2.10 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.55 EUR, the upside of Innate Pharma SA is -235.70%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -20.76 | -63.98 | -52.81 | -58.10 | -7.57 | -40.65 |
| YoY growth | -780.40% | -208.22% | 17.47% | -10.02% | 86.97% | -178.84% |
| Market Cap (mil) | 125.47 |
| P/E | |
| Forward P/E |
| EPS | -0.42 |
| Avg earnings growth rate | -178.84% |
| TTM earnings | -34.05 |